Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell...

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Minimal residual disease (MRD) testing is crucial for monitoring multiple myeloma (MM) treatment response.
• MRD progression (MRD-P) often precedes clinical progression (PD), creating uncertainty in treatment timing.

Purpose of the Study:

• To investigate the impact of early intervention (EI) versus delayed treatment (PD) on prognosis in newly diagnosed MM patients with MRD-P.
• To evaluate survival outcomes and MRD re-negativity rates associated with EI in MM patients post-autologous stem cell transplantation.

Main Methods:

• Retrospective analysis of 42 newly diagnosed MM patients who developed MRD-P after initial treatment.
• Comparison between an EI group (n=9) with modified treatment at MRD-P onset and a PD group (n=33) with delayed treatment until clinical progression.
• Median follow-up of 25 months.

Main Results:

• The EI group showed significantly longer time to progression (34.8 vs. 6.6 months, p=0.029) and superior overall survival (median not reached vs. 41.0 months, p=0.034) compared to the PD group.
• MRD re-negativity rates were significantly higher and achieved faster in the EI group (median 12.6 vs. 75.9 months, p<0.001).
• Multivariate analysis confirmed EI was associated with improved MRD re-negativity (HR=0.07; p=0.001).

Conclusions:

• Early intervention upon MRD progression in MM patients may improve survival outcomes and increase MRD re-negativity rates.
• Findings suggest that modifying treatment at MRD-P onset warrants consideration, despite study limitations.
• This hypothesis-generating study provides preliminary data for designing future prospective randomized trials in MM management.